Asanuma Sakae 4
4 · Werewolf Therapeutics, Inc. · Filed May 4, 2021
Insider Transaction Report
Form 4
Asanuma Sakae
Director10% Owner
Transactions
- Conversion
Common Stock
2021-05-04+1,318,311→ 1,318,311 total(indirect: See footnote) - Conversion
Common Stock
2021-05-04+438,098→ 1,756,409 total(indirect: See footnote) - Purchase
Common Stock
2021-05-04$16.00/sh+312,500$5,000,000→ 2,068,909 total(indirect: See footnote) - Purchase
Series B Preferred Stock
2020-12-23$0.92/sh+3,797,921$3,499,404→ 3,797,921 total(indirect: See footnote)→ Common Stock (438,098 underlying) - Conversion
Series B Preferred Stock
2021-05-04−3,797,921→ 0 total(indirect: See footnote)→ Common Stock (438,098 underlying) - Conversion
Series A Preferred Stock
2021-05-04−11,428,570→ 0 total(indirect: See footnote)→ Common Stock (1,318,311 underlying)
Footnotes (4)
- [F1]On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC.
- [F3]On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F4]The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.